The Mirage of AI Driven Cancer Cures: A Reckoning Overhyped and Underprepared The notion that artificial intelligence will single handedly cure cancer has become a tired trope in the tech world, often used to justify grandiose claims.
Beneath this hype lies a stark reality: despite significant investment, AI powered drug discovery remains woefully underprepared for the complexity of human biology.
Vivodyne, a biotech startup, is the latest entrant into this arena with its bold vision for accelerating the path to new cancer treatments using modular robotic labs called HIVE.